

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 July 2020 (23.07.2020)



(10) International Publication Number
WO 2020/150136 A1

(51) International Patent Classification:

C07D 413/14 (2006.01) A61K 31/422 (2006.01)
A61P 1/16 (2006.01)

(21) International Application Number:

PCT/US2020/013319

(22) International Filing Date:

13 January 2020 (13.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/792,714 15 January 2019 (15.01.2019) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: BLOMGREN, Peter A.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). CURRIE, Kevin S.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). FRICK, Morin Mae; 3001 Los Prados Street, #205, San Mateo, California 94403 (US). HORSTMAN, Elizabeth M.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). KAPLAN, Joshua A.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). KROPF, Jeffrey E.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). WATKINS, William J.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: SIMPSON, Alexis N. et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: FXR (NR1H4) MODULATING COMPOUNDS



(I)

(57) Abstract: The present disclosure relates generally to a compound of formula (I) that binds to FXR and acts as agonists of FXR. The disclosure further relates to the use of the compound for the preparation of a medication for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compound.

WO 2020/150136 A1